New hope for IIH headache sufferers: migraine drug tested in landmark trial
NCT ID NCT07645833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether eptinezumab, a drug used for migraines, can reduce the number of headache days in adults with idiopathic intracranial hypertension (IIH), a condition where high fluid pressure around the brain causes severe headaches. About 96 women aged 18-55 with chronic headaches will receive either the drug or a placebo. The goal is to see if the drug lowers monthly moderate-to-severe headache days and improves quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INTRACRANIAL HYPERTENSION (IIH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain stent trial aims to ease pressure headaches and save sight
- Can losing weight cure a brain pressure disorder? new study investigates
- Brain vein stent could ease pressure for IIH patients
- Could a diabetes drug ease brain pressure?
- Brain vein stent could ease pressure and save sight in IIH patients